- Home
- JGH vs CRMD Comparison
JGH vs CRMD Comparison
Compare JGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | CRMD |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 509.9M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | JGH | CRMD |
|---|---|---|
| Price | $11.91 | $6.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 89.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $10.51 | $5.60 |
| 52 Week High | $13.70 | $17.43 |
Technical Indicators
Market Signals| Indicator | JGH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 25.35 | 47.74 |
| Support Level | N/A | $6.55 |
| Resistance Level | $12.92 | $7.44 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 5.26 | 67.54 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.